Logo for Synlogic Inc

Synlogic Investor Relations Material

Latest events

Logo for Synlogic Inc

Q2 2022

Logo for Synlogic

Q4 2023

19 Mar, 2024
Logo for Synlogic

Q3 2023

9 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Synlogic Inc

Access all reports
Synlogic, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases. Synlogic’s product candidates include SL-401, which is a drug candidate for the treatment of Type 1 Diabetes Mellitus, a rare metabolic disease; SL-701, which is an orally administered synthetic biotic therapeutic designed to regulate the gut microbiome to protect against Clostridium difficile infection; and SL-701 as a treatment for Multiple Sclerosis.